Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Angioma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Angioma. Displaying page 1 of 1.
    EudraCT Number: 2010-022440-20 Sponsor Protocol Number: 10-PP-11 Start Date*: Information not available in EudraCT
    Sponsor Name:CHU de Nice
    Full Title: Traitements of angioma plans of the child by laser to pulsed colouring agent and Timolol (Néogel 0,1%).
    Medical condition: Angioma plans
    Disease: Version SOC Term Classification Code Term Level
    12.1 10002461 Angioma of skin LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-000202-36 Sponsor Protocol Number: CHUBX 2007/27 Start Date*: 2008-06-12
    Sponsor Name:CHU de Bordeaux
    Full Title: Etude clinique randomisée du propranolol versus placebo dans le traitement des hémangiomes capillaires infantiles.
    Medical condition: Hémangiomes capillaires
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019386 Hemangioma LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018102-22 Sponsor Protocol Number: V00400SB102 Start Date*: 2010-03-26
    Sponsor Name:PIERRE FABRE DERMATOLOGIE
    Full Title: A multicentre, open-label, repeated-dose, pharmacokinetic study of Propranolol in infants treated for proliferating infantile hemangiomas (IHs) requiring systemic therapy.
    Medical condition: Proliferating Infantile Hemangioma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018814 Haemangioma LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023488-16 Sponsor Protocol Number: V00400SB301 Start Date*: 2011-02-10
    Sponsor Name:PIERRE FABRE DERMATOLOGIE represented by INSTITUT DE RECHERCHE PIERRE FABRE
    Full Title: A multicentre, open-label study of propranolol in infants with proliferating infantile hemangioma requiring systemic therapy
    Medical condition: Proliferating Infantile Hemangioma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018814 Haemangioma LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-017241-55 Sponsor Protocol Number: RC 43/08 Start Date*: 2009-12-09
    Sponsor Name:ISTITUTO PER L`INFANZIA BURLO GAROFOLO
    Full Title: Open randomized study on propranolol vs prednisone for haemangioma in patients younger than 18 months of age
    Medical condition: Haemagiomas
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018823 Haemangioma of skin LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019754-41 Sponsor Protocol Number: PROHÄM Start Date*: 2010-10-19
    Sponsor Name:InfectoPharm Arzneimittel und Consilium GmbH
    Full Title: Multizentrische, prospektive, einarmige Phase III-Studie zur Wirksamkeit und Sicherheit einer oralen Therapie mit Propranolol (ProAngiol Saft; 2 mg/kg KG/d mit fakultativer Dosiserhöhung auf 3 mg/k...
    Medical condition: Hemangioma in infants and toddlers, requiring systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019386 Hemangioma LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005555-80 Sponsor Protocol Number: V00400SB302 Start Date*: 2015-05-21
    Sponsor Name:Pierre Fabre Dermatologie represented by IRPF
    Full Title: Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational Single Arm Study
    Medical condition: High risk infantile haemangioma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018814 Haemangioma PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-013262-84 Sponsor Protocol Number: V00400SB201 Start Date*: 2009-10-28
    Sponsor Name:PIERRE FABRE DERMATOLOGIE
    Full Title: A randomised, controlled, multidose, multicentre, adaptive phase II/III study in infants with proliferating infantile hemangiomas requiring systemic therapy to compare four regimens of propranolol ...
    Medical condition: Proliferating Infantile Hemangioma
    Disease: Version SOC Term Classification Code Term Level
    12.0 10018814 Haemangioma LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IT (Completed) HU (Completed) LT (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-014571-49 Sponsor Protocol Number: CDP0901 Start Date*: 2010-01-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: The use of systemic propranolol in congenital hemangiomas
    Medical condition: congenital hemangiomas
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018818 Haemangioma congenital LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012115-18 Sponsor Protocol Number: IMP13617 Start Date*: 2010-03-22
    Sponsor Name:UMC Utrecht
    Full Title: Primovist enhanced MRI for the detection and evaluation of focal liver lesions
    Medical condition: All benign and malignant focal liver lesions e.g. colorectal liver metastases, HCC, haemangioma, adenoma, cysts, FNH.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10024658 Liver carcinoma LLT
    12.0 10027479 Metastatic liver carcinoma LLT
    12.0 10019827 Hepatocellular adenoma LLT
    12.0 10049010 Carcinoma hepatocellular LLT
    12.0 10019396 Hemangioma of liver LLT
    12.0 10048834 Polycystic liver disease LLT
    12.0 10052285 Focal nodular hyperplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024078-20 Sponsor Protocol Number: RSW2011 Start Date*: 2011-05-11
    Sponsor Name:Instituto Científico y Tecnológico de Navarra
    Full Title: Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pu...
    Medical condition: Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber.
    Disease: Version SOC Term Classification Code Term Level
    13 10042265 Síndrome de Sturge-Weber PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2017-003272-31 Sponsor Protocol Number: NL.EPITRAC.0107.17 Start Date*: 2018-05-18
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasia
    Medical condition: Severe epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    20.0 100000004850 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003982-24 Sponsor Protocol Number: HHT-HOPE-2016 Start Date*: 2017-03-16
    Sponsor Name:Asociación HHT España
    Full Title: A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of...
    Medical condition: Hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10020023 HHT LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001455-37 Sponsor Protocol Number: 1331TMF Start Date*: 2011-12-21
    Sponsor Name:Department of Radiology, Oslo University Hospital, Norway
    Full Title: Prospective randomized interventional study. Compare the effect of bleomycin and Tetradecyl Sodium Sulphate (Fibrovein) in the treatment of venous malformations. Clinical neurological and neurophys...
    Medical condition: Venous malformation
    Disease: Version SOC Term Classification Code Term Level
    13.1 10010331 - Congenital, familial and genetic disorders 10047229 Venous malformation NOS LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004096-36 Sponsor Protocol Number: THALI-HHT Start Date*: 2011-10-11
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia (HHT)
    Medical condition: Severe recurrent epistaxis in hereditary hemorrhagic telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10038554 Rendu-Osler-Weber syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000385-55 Sponsor Protocol Number: 69HCL15_0063 Start Date*: 2015-05-12
    Sponsor Name:Hospices Civils de Lyon
    Full Title: TEMPO : Efficacité du TIMOLOL en administration nasale pour le traitement des épistaxis dans la maladie de Rendu-Osler. Essai randomisé en double insu contre placebo
    Medical condition: Rendu-Osler disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004204-19 Sponsor Protocol Number: 2013-827 Start Date*: 2014-02-26
    Sponsor Name:Hospices Civils de Lyon
    Full Title: Efficacité du bevacizumab en spray nasal pour le traitement des épistaxis dans la maladie de Rendu-Osler
    Medical condition: Rendu-Osler disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-006755-44 Sponsor Protocol Number: 2008-510 Start Date*: 2009-01-15
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: METAFORE : Maladie de Rendu-Osler : Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase II
    Medical condition: Maladie de Rendu-Osler
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004179-11 Sponsor Protocol Number: 2018-4898 Start Date*: 2019-06-03
    Sponsor Name:Radboudumc
    Full Title: Effectiveness of Somatostatin Analogues in Patients with hereditary hemorrhagic telangiectasia and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, pa...
    Medical condition: Hereditary hemorrhagic telangiectasia (HHT)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Ongoing) FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA